IRIS
PINATO, David James
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 9.183
EU - Europa 6.574
AS - Asia 6.509
SA - Sud America 850
Continente sconosciuto - Info sul continente non disponibili 380
AF - Africa 340
OC - Oceania 6
Totale 23.842
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.752
SG - Singapore 2.520
RU - Federazione Russa 2.467
IE - Irlanda 1.239
CN - Cina 1.194
HK - Hong Kong 1.156
IT - Italia 652
BR - Brasile 621
VN - Vietnam 574
DE - Germania 434
FR - Francia 424
SE - Svezia 371
GB - Regno Unito 270
BD - Bangladesh 264
UA - Ucraina 218
CA - Canada 210
BJ - Benin 206
IN - India 174
KR - Corea 157
FI - Finlandia 98
AT - Austria 96
MX - Messico 93
JP - Giappone 80
AR - Argentina 74
ES - Italia 62
PL - Polonia 59
ID - Indonesia 55
ZA - Sudafrica 52
NL - Olanda 46
IQ - Iraq 44
TR - Turchia 44
CO - Colombia 41
IR - Iran 33
EC - Ecuador 31
PK - Pakistan 30
LT - Lituania 29
PH - Filippine 27
MA - Marocco 26
VE - Venezuela 26
CR - Costa Rica 23
JM - Giamaica 19
SA - Arabia Saudita 19
CL - Cile 18
CZ - Repubblica Ceca 18
EE - Estonia 16
AE - Emirati Arabi Uniti 15
PY - Paraguay 15
UZ - Uzbekistan 15
BE - Belgio 14
CH - Svizzera 14
GT - Guatemala 13
HN - Honduras 13
TT - Trinidad e Tobago 12
OM - Oman 11
MY - Malesia 10
EG - Egitto 9
JO - Giordania 9
NI - Nicaragua 9
NP - Nepal 9
TN - Tunisia 9
IL - Israele 8
KE - Kenya 8
PE - Perù 8
BO - Bolivia 7
ET - Etiopia 7
RS - Serbia 7
SV - El Salvador 7
TH - Thailandia 7
UY - Uruguay 7
BS - Bahamas 6
DO - Repubblica Dominicana 6
DZ - Algeria 6
KZ - Kazakistan 6
PS - Palestinian Territory 6
PT - Portogallo 6
TW - Taiwan 6
BG - Bulgaria 5
CW - ???statistics.table.value.countryCode.CW??? 5
LB - Libano 5
SN - Senegal 5
AU - Australia 4
AZ - Azerbaigian 4
BH - Bahrain 4
SK - Slovacchia (Repubblica Slovacca) 4
AM - Armenia 3
BB - Barbados 3
BZ - Belize 3
CY - Cipro 3
DK - Danimarca 3
EU - Europa 3
GP - Guadalupe 3
HU - Ungheria 3
KG - Kirghizistan 3
LC - Santa Lucia 3
LV - Lettonia 3
MN - Mongolia 3
PR - Porto Rico 3
SY - Repubblica araba siriana 3
BA - Bosnia-Erzegovina 2
BF - Burkina Faso 2
Totale 23.429
Salva come PNG Salva come JPEG
Città #
San Jose 1.438
Dublin 1.236
Hong Kong 1.145
Singapore 972
Council Bluffs 763
Ashburn 711
Beijing 309
Moscow 296
Los Angeles 293
Phoenix 269
Lauterbourg 246
Santa Clara 242
Columbus 208
Cotonou 206
Buffalo 161
Ho Chi Minh City 160
New York 158
Princeton 151
Jacksonville 150
Lawrence 149
Wilmington 142
Hanoi 140
Seoul 137
San Mateo 125
Dallas 115
Chandler 114
Chicago 79
Falkenstein 76
São Paulo 74
Orem 70
Brooklyn 69
Novara 67
Nuremberg 67
Tokyo 65
Toronto 61
Helsinki 58
Denver 56
Chennai 55
Dearborn 55
Frankfurt am Main 55
Mexico City 52
Milan 51
Vienna 51
Redondo Beach 48
Schaumburg 47
Piemonte 46
St Louis 46
Montreal 45
Warsaw 44
London 43
Olathe 43
Tianjin 42
Munich 41
Atlanta 40
Boston 39
Houston 39
Ann Arbor 38
North Bergen 37
Assago 36
Stockholm 35
Haiphong 34
Johannesburg 34
Hangzhou 33
Guangzhou 32
Turin 32
Boardman 31
Rome 31
San Francisco 31
Da Nang 30
Manchester 28
Amsterdam 27
Poplar 27
Shanghai 25
Vercelli 25
Andover 23
Philadelphia 23
Brasília 22
Jakarta 22
Mumbai 22
Strasbourg 22
Shenzhen 20
Ankara 18
Bremen 18
Las Vegas 18
Seattle 18
Norwalk 17
Newark 16
Zanjan 16
Dhaka 15
Naples 15
San José 15
The Dalles 15
Quito 14
Roubaix 14
Brussels 13
Genoa 13
Guatemala City 13
Tashkent 13
The Bronx 13
Washington 13
Totale 12.667
Salva come PNG Salva come JPEG
Nome #
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease 199
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry 192
Long-term sequelae are highly prevalent one year after hospitalization for severe COVID-19 167
Determinants of long COVID among adults hospitalized for SARS-CoV-2 infection: A prospective cohort study 166
On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma: a multi-centre, prospective study 165
Time-Dependent COVID-19 Mortality in Patients with Cancer: An Updated Analysis of the OnCovid Registry 154
Validation of the Hepatoma Arterial Embolization Prognostic Score in European and Asian Populations and Proposed Modification. 152
L’impatto del Long COVID è stato minore nella terza ondata della pandemia rispetto alla prima ondata in una popolazione italiana di 324 pazienti. 149
Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma 148
COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry 148
Evaluation of the red cell distribution width as a biomarker of early mortality in hepatocellular carcinoma 147
Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study 144
Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: The OnCovid Inflammatory Score 143
Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib 142
PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort 142
Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours 142
Hepatic decompensation is the major driver of mortality in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: The impact of successful antiviral treatment 141
Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: A multi-center comparative study 139
Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer 136
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry 134
Presenting features and early mortality from SARS-CoV-2 infection in cancer patients during the initial stage of the COVID-19 pandemic in Europe 133
Prevalence and impact of COVID-19 sequelae on treatment pathways and survival of patients with cancer who recovered from SARS-Cov-2 infection: results from the OnCovid registry. 132
Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients 131
Early hepatic decompensation identifies patients with hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab or Sorafenib at highest risk of death 130
Pandemic Phase-Adjusted Analysis of COVID-19 Outcomes Reveals Reduced Intrinsic Vulnerability and Substantial Vaccine Protection From Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Breast Cancer 129
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma 128
Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study 124
Immunotherapy vs Best Supportive Care for Patients with Hepatocellular Cancer with Child-Pugh B Dysfunction 123
The ALBI grade provides objective hepatic reserve estimation across each BCLC stage of hepatocellular carcinoma 122
Safety and Preliminary Efficacy of Pembrolizumab Following Transarterial Chemoembolization for Hepatocellular Carcinoma: The PETAL Phase Ib Study 121
Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab 120
Predictive ability of a drug-based score in patients with advanced non–small-cell lung cancer receiving first-line immunotherapy 120
Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries 119
Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study 119
Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer 116
Activation and transcriptional profile of monocytes and CD8+ T cells are altered in checkpoint inhibitor-related hepatitis 116
Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter? 115
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: a cross-trial, patient-level analysis 115
Predictive biomarkers of response to immune checkpoint inhibitors in hepatocellular carcinoma 115
Prognostic sub-classification of intermediate-stage hepatocellular carcinoma: a multicenter cohort study with propensity score analysis. 114
Impact of age on sorafenib outcomes in hepatocellular carcinoma: an international cohort study 114
Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer 113
Delivering adjuvant and neoadjuvant treatments in the early stages of hepatocellular carcinoma 112
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC 111
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma 110
High familial burden of cancer correlates with improved outcome from immunotherapy in patients with NSCLC independent of somatic DNA damage response gene status 110
HBV AND LYMPHOMAGENESIS: NOVEL INSIGHTS INTO AN OCCULT RELATIONSHIP 110
Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma 109
NASH limits anti-tumour surveillance in immunotherapy-treated HCC 109
ALBI grade: Evidence for an improved model for liver functional estimation in patients with hepatocellular carcinoma 108
Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study 107
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy 107
Merits and boundaries of the BCLC staging and treatment algorithm: Learning from the past to improve the future with a novel proposal 106
T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma 106
Hepatitis B virus and lymphomagenesis: novel insights into an occult relationship 105
Immunotherapies for hepatocellular carcinoma 104
Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: A systematic review 104
Comparative efficacy of novel combination strategies for unresectable hepatocellular carcinoma: A network metanalysis of phase III trials 104
Disturbances in sodium and chloride homeostasis predict outcome in stable and critically ill patients with cirrhosis 104
Immune Checkpoint Inhibitors for Child-Pugh Class B Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis 103
The albumin–bilirubin grade improves hepatic reserve estimation post-sorafenib failure: implications for drug development 103
Advanced age influences the dynamic changes in circulating C-reactive protein following injury 103
Antibiotic therapy and outcome from immune-checkpoint inhibitors 103
T-cell mediated responses against alpha-foetoprotein in hepatocellular carcinoma: Relationship with hepatitis C virus infection, tumour phenotype and patients’ survival 103
Previous immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry 102
Outcome and management of patients with hepatocellular carcinoma who achieved complete response to immunotherapy-based systemic therapy 102
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study 102
Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations 102
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma 101
Treatment Stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study 101
Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors 100
Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study 100
Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis 99
A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC 98
A Pilot Randomized, Placebo Controlled, Double Blind Phase I Trial of the Novel SIRT1 Activator SRT2104 in Elderly Volunteers 98
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma 97
Phenotypic Characteristics of the Tumour Microenvironment in Primary and Secondary Hepatocellular Carcinoma 97
Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis 96
Untargeted lipidomics reveal association of elevated plasma C18 ceramide levels with reduced survival in metastatic castration-resistant prostate cancer patients 95
Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma 95
Acceleration of interstitial lung disease induced by raltitrexed 94
Refining patient selection for next-generation immunotherapeutic early-phase clinical trials with a novel and externally validated prognostic nomogram 93
Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice 93
Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade 93
A novel and validated prognostic index in hepatocellular carcinoma: The inflammation based index (IBI) 92
Prior antibiotics, proton pump inhibitors, and probiotics in patients with extensive stage small cell lung cancer treated with immune checkpoint blockade: A post-hoc analysis of the phase I/III IMpower 133 trial 91
A New Prognostic Model in Patients with Advanced Urothelial Carcinoma Treated with First-line Immune Checkpoint Inhibitors 91
Integrated phenotyping of the anti-cancer immune response in HIV-associated hepatocellular carcinoma 90
Longitudinal Body Composition Identifies Hepatocellular Carcinoma With Cachexia Following Combined Immunotherapy and Target Therapy (CHANCE2213) 90
A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma 90
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET Fusion 90
An inflammation based score can optimize the selection of patients with advanced cancer considered for early phase clinical trials 90
Knowledge and attitudes of Italian medical oncologists and palliative care physicians toward medical use of cannabis in cancer care: a national survey 90
Efficacy of transarterial radioembolization using Y-90 resin microspheres versus atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A matching-adjusted indirect comparison 89
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma 89
An expression signature of the angiogenic response in gastrointestinal neuroendocrine tumours: Correlation with tumour phenotype and survival outcomes 89
Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy 89
A multicentre study of pembrolizumab time-of-day infusion patterns and clinical outcomes in non-small-cell lung cancer: too soon to promote morning infusions 89
The price and value of therapeutic synergy in liver cancer 87
A novel, externally validated inflammation-based prognostic algorithm in hepatocellular carcinoma: The prognostic nutritional index (PNI) 87
Totale 11.451
Salva come PNG Salva come JPEG
Categoria #
all - tutte 128.730
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 128.730
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022596 0 0 0 71 46 6 24 21 68 63 126 171
2022/20231.810 217 43 77 6 51 106 43 79 1.132 5 27 24
2023/20241.084 136 46 82 33 209 14 222 15 4 39 56 228
2024/20253.885 45 26 204 19 36 331 391 346 904 590 261 732
2025/202611.855 548 499 678 1.060 1.303 833 1.964 1.777 881 927 857 528
2026/20273.579 455 982 1.027 1.115 0 0 0 0 0 0 0 0
Totale 23.842